Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. A

Go back to Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC
Merck & Co. (NYSE: MRK) Delayed: 151.47 -1.63 (1.06%)
Previous Close $153.10    52 Week High $65.46 
Open $149.53    52 Week Low $47.97 
Day High $151.49    P/E 103.04 
Day Low $149.02    EPS $1.47 
Volume 2,135,073